Journal of HIV Therapy

COPYRIGHT TV Trade Media, Inc.
COPYRIGHT GALE, Cengage Learning. All rights reserved.

COPYRIGHT GALE, Cengage Learning. All rights reserved

from June 2007
Last Number: March 2010

Mediscript Ltd.
ISSN 1462-0308


Browse by Number

Vol. 15 Nbr. 1, March 2010

SILCAAT and ESPRIT: taking stock.

Study of interleukin-2 in people with low CD4+ T cell counts on active anti-HIV therapy - Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy - Editorial

HIV immunology: what lessons can we learn from recent vaccine trials?

LEADING ARTICLE - Human immunodeficiency virus - Report

Lymphocyte activation in HIV-1 infection: time for quality control.

LEADING ARTICLE - Human immunodeficiency virus - Report

A review of the use of activation markers in Africa.

LEADING ARTICLE - Report

Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.

LEADING ARTICLE - Human immunodeficiency virus - Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy - Study of interleukin-2 in people with low CD4+ T cell counts on active anti-human immunodeficiency virus therapy - Report


ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2017, vLex. All Rights Reserved.

Contents in vLex United States

Explore vLex

For Professionals

For Partners